Ab­b­Vie set­tles one of its fi­nal Hu­mi­ra biosim­i­lar suits for an­oth­er mid-2023 de­layed en­try

Ab­b­Vie’s block­buster rheuma­toid arthri­tis drug Hu­mi­ra will see even more com­pe­ti­tion next year, as Ab­b­Vie and biosim­i­lar de­vel­op­er Alvotech set­tled a court dis­pute over when the com­pa­ny’s adal­i­mum­ab biosim­i­lar can launch, even as the drug has yet to be ap­proved by the FDA.

The set­tle­ment ful­ly re­solves all pend­ing le­gal US dis­putes be­tween Ab­b­Vie and Alvotech re­lat­ed to the biosim­i­lar, which re­moves any bar­ri­ers block­ing Alvotech’s high-con­cen­tra­tion ver­sion of adal­i­mum­ab from reach­ing US pa­tients on Ju­ly 1, 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.